 |
 |
TAU Research Leads to Next Stage in New Parkinson's Treatment BrainStorm, a company developed on research licensed from Tel Aviv University, announced last week that it has started its animal model study on stem cell treatments against Parkinson's disease. The study is being carried out in collaboration with the Center for Applied Medical Research (CIMA) of the University of Navarra in Pamplona, Spain. The team at the Movement Disorders Unit at the University has over 20 years experience in researching and applying new therapies to treat Parkinson's Disease, and anticipates being among the first to use BrainStorm's technology to treat patients in its own University Hospital. BrainStorm's Chief Medical Advisor is Prof. Melamed - a world-renowned expert in the field of neurodegenerative diseases - particularly on Parkinson's disease. Prof. Melamed has served as head of the Neurology Department at the Rabin Medical Center and Tel Aviv University since 1987. Throughout his career, Prof. Melamed has specialized in neurology, holding senior positions at the National Hospital (London) and at the Laboratory of Neuroendocrine Regulation (Massachusetts). He is a past president of the Israel Neurological Association and former director of the National Parkinson Foundation (USA). Prof. Melamed is a member of the Scientific Committee of the Michael J Fox Foundation for Parkinson's Research. In addition to moving ahead with the company's Parkinson's Disease program, Prof. Melamed is also helping BrainStorm progress with pre-clinical trials applying the company's stem cell technology to the treatment of ALS and Multiple Sclerosis. BrainStorm holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel Aviv University. The Company's initial focus is on Parkinson's disease, although its technology has promise for treating several others diseases including MS, ALS, Huntington's disease and strokes. ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn